265 related articles for article (PubMed ID: 32184591)
1. Aptamer-Conjugated Gold Nanoparticles Targeting Epidermal Growth Factor Receptor Variant III for the Treatment of Glioblastoma.
Peng L; Liang Y; Zhong X; Liang Z; Tian Y; Li S; Liang J; Wang R; Zhong Y; Shi Y; Zhang X
Int J Nanomedicine; 2020; 15():1363-1372. PubMed ID: 32184591
[TBL] [Abstract][Full Text] [Related]
2. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
[TBL] [Abstract][Full Text] [Related]
3. Effects of Aptamer to U87-EGFRvIII Cells on the Proliferation, Radiosensitivity, and Radiotherapy of Glioblastoma Cells.
Zhang X; Peng L; Liang Z; Kou Z; Chen Y; Shi G; Li X; Liang Y; Wang F; Shi Y
Mol Ther Nucleic Acids; 2018 Mar; 10():438-449. PubMed ID: 29499954
[TBL] [Abstract][Full Text] [Related]
4. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
5. Cell-SELEX aptamer for highly specific radionuclide molecular imaging of glioblastoma in vivo.
Wu X; Liang H; Tan Y; Yuan C; Li S; Li X; Li G; Shi Y; Zhang X
PLoS One; 2014; 9(6):e90752. PubMed ID: 24603483
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
[TBL] [Abstract][Full Text] [Related]
7. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J
Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231
[TBL] [Abstract][Full Text] [Related]
8. JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.
Zheng Q; Han L; Dong Y; Tian J; Huang W; Liu Z; Jia X; Jiang T; Zhang J; Li X; Kang C; Ren H
Neuro Oncol; 2014 Sep; 16(9):1229-43. PubMed ID: 24861878
[TBL] [Abstract][Full Text] [Related]
9. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
Keir ST; Chandramohan V; Hemphill CD; Grandal MM; Melander MC; Pedersen MW; Horak ID; Kragh M; Desjardins A; Friedman HS; Bigner DD
J Neurooncol; 2018 Jul; 138(3):489-498. PubMed ID: 29564747
[TBL] [Abstract][Full Text] [Related]
10. EGFR Activates a TAZ-Driven Oncogenic Program in Glioblastoma.
Gao M; Fu Y; Zhou W; Gui G; Lal B; Li Y; Xia S; Ji H; Eberhart CG; Laterra J; Ying M
Cancer Res; 2021 Jul; 81(13):3580-3592. PubMed ID: 33910930
[TBL] [Abstract][Full Text] [Related]
11. DNA aptamers that target human glioblastoma multiforme cells overexpressing epidermal growth factor receptor variant III in vitro.
Tan Y; Shi YS; Wu XD; Liang HY; Gao YB; Li SJ; Zhang XM; Wang F; Gao TM
Acta Pharmacol Sin; 2013 Dec; 34(12):1491-8. PubMed ID: 24304919
[TBL] [Abstract][Full Text] [Related]
12. Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma.
Dréan A; Lemaire N; Bouchoux G; Goldwirt L; Canney M; Goli L; Bouzidi A; Schmitt C; Guehennec J; Verreault M; Sanson M; Delattre JY; Mokhtari K; Sottilini F; Carpentier A; Idbaih A
J Neurooncol; 2019 Aug; 144(1):33-41. PubMed ID: 31197598
[TBL] [Abstract][Full Text] [Related]
13. EGFRvIII/integrin β3 interaction in hypoxic and vitronectinenriching microenvironment promote GBM progression and metastasis.
Liu Z; Han L; Dong Y; Tan Y; Li Y; Zhao M; Xie H; Ju H; Wang H; Zhao Y; Zheng Q; Wang Q; Su J; Fang C; Fu S; Jiang T; Liu J; Li X; Kang C; Ren H
Oncotarget; 2016 Jan; 7(4):4680-94. PubMed ID: 26717039
[TBL] [Abstract][Full Text] [Related]
14. Expression and pharmacological inhibition of TrkB and EGFR in glioblastoma.
Pinheiro KV; Thomaz A; Souza BK; Metcalfe VA; Freire NH; Brunetto AT; de Farias CB; Jaeger M; Bambini V; Smith CGS; Shaw L; Roesler R
Mol Biol Rep; 2020 Sep; 47(9):6817-6828. PubMed ID: 32862352
[TBL] [Abstract][Full Text] [Related]
15. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.
Chou ST; Patil R; Galstyan A; Gangalum PR; Cavenee WK; Furnari FB; Ljubimov VA; Chesnokova A; Kramerov AA; Ding H; Falahatian V; Mashouf L; Fox I; Black KL; Holler E; Ljubimov AV; Ljubimova JY
J Control Release; 2016 Dec; 244(Pt A):14-23. PubMed ID: 27825958
[TBL] [Abstract][Full Text] [Related]
17. Brain Targeted Gold Liposomes Improve RNAi Delivery for Glioblastoma.
Grafals-Ruiz N; Rios-Vicil CI; Lozada-Delgado EL; Quiñones-Díaz BI; Noriega-Rivera RA; Martínez-Zayas G; Santana-Rivera Y; Santiago-Sánchez GS; Valiyeva F; Vivas-Mejía PE
Int J Nanomedicine; 2020; 15():2809-2828. PubMed ID: 32368056
[TBL] [Abstract][Full Text] [Related]
18. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.
Costa B; Bendinelli S; Gabelloni P; Da Pozzo E; Daniele S; Scatena F; Vanacore R; Campiglia P; Bertamino A; Gomez-Monterrey I; Sorriento D; Del Giudice C; Iaccarino G; Novellino E; Martini C
PLoS One; 2013; 8(8):e72281. PubMed ID: 23977270
[TBL] [Abstract][Full Text] [Related]
19. FHL2 interacts with EGFR to promote glioblastoma growth.
Sun L; Yu S; Xu H; Zheng Y; Lin J; Wu M; Wang J; Wang A; Lan Q; Furnari F; Cavenee W; Purow B; Li M
Oncogene; 2018 Mar; 37(10):1386-1398. PubMed ID: 29321665
[TBL] [Abstract][Full Text] [Related]
20. EGFRvIII expression triggers a metabolic dependency and therapeutic vulnerability sensitive to autophagy inhibition.
Jutten B; Keulers TG; Peeters HJM; Schaaf MBE; Savelkouls KGM; Compter I; Clarijs R; Schijns OEMG; Ackermans L; Teernstra OPM; Zonneveld MI; Colaris RME; Dubois L; Vooijs MA; Bussink J; Sotelo J; Theys J; Lammering G; Rouschop KMA
Autophagy; 2018; 14(2):283-295. PubMed ID: 29377763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
